New Key Statistics Module, Z-Score and F-Score
NAS:ARQT Key Ratios
| Market Cap $ M | 905.72 |
| Enterprise Value $ M | 839.77 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 8.56 |
| Price/Sales | 8.79 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 59.00 |
| EPS (TTM) $ | -3.92 |
| Beneish M-Score | 9.96 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -33.10 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -3.66 |
| EV-to-EBITDA | -3.69 |
| PEG | -- |
| Shares Outstanding M | 115.52 |
| Net Margin (%) | -439.79 |
| Operating Margin % | -404.49 |
| Pre-tax Margin (%) | -434.67 |
| Quick Ratio | 6.80 |
| Current Ratio | 7.08 |
| ROA % (ttm) | -73.48 |
| ROE % (ttm) | -231.90 |
| ROIC % (ttm) | -830.65 |
| Dividend Yield % | -- |
| Altman Z-Score | -2.92 |
ARQT Number of Guru Trades
ARQT Volume of Guru Trades
Gurus Latest Trades with NAS:ARQT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:ARQT is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Arcutis Biotherapeutics Inc Insider Transactions
No Available Data
News about NAS:ARQT
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers